WHO - Over 1 million treated with highly effective hepatitis C medicines
High prices–a major barrier to access
GENEVA - Over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.
When Direct Acting Antivirals (DAAs) were first approved for hepatitis C treatment in 2013, there were widespread fears that their high price would put them out of reach for the more than 80 million people with chronic hepatitis C infections worldwide.
The new medicines have a cure rate of over 95%, fewer side effects than previously available therapies, and can completely cure the disease within three months. But at an initial estimated price of some US$85 000 they were unaffordable even in high-income countries. (WHO, 27.10.2016)
http://www.who.int/mediacentre/news/releases/2016/hepatitis-c-medicines/en/